National Conference of the Italian Group for the Study of Neuromorphology
Vol. 70 No. s2 (2026): 36th National Conference of the Italian Group for the Study of...

P011 | THE POTENTIAL OF VGF-DERIVED PRODUCTS AS PREDICTIVE BIOMARKERS OF PARKINSON’S DISEASE

A.L. Manai1, B. Noli1, A. Anjum1, M.M. Mascia2, M. Meloni2, K.I.R.M. Humaidan2, R.A. Filiberti3, M. Puligheddu2, C. Cocco1 | 1Department of Biomedical Sciences, NEF-Laboratory, University of Cagliari, Monserrato (CA), Italy; 2Neurology Unit, University Hospital of Cagliari, Italy; 3Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 November 2026
0
Views
0
Downloads

Authors

The prodromal phase of Parkinson’s disease (PD) is characterized by non-motor manifestations, particularly idiopathic REM sleep behavior disorder (iRBD), reflecting early neural dysfunction before the onset of motor symptoms. Reliable biomarkers for this stage are still lacking. VGF is a neurosecretory precursor protein processed into multiple bioactive derived products. In PD drug-naive patients (PDN), VGF changes, involving the C-terminus region of proVGF, have been revealed compared to controls using ELISA through an antibody against the C-terminus of proVGF. Whether these changes are associated with prodromal non-motor symptoms in humans remains unclear. The present study aimed to assess whether individuals with iRBD and PDN exhibit a common pattern of alterations in specific C-terminal VGF-derived products previously found to be changed in prodromal PD models, supporting their potential utility as biomarkers of early PD-related pathology. The clinical cohort included PD-naive patients (PDN; N = 20), levodopa-treated PD patients (N = 40; subdivided into short-term N = 19 and long-term treated groups N = 21), iRBD patients (N = 20), and age-matched controls (N = 39). Among the other diseases, were collected patients affected by multiple sclerosis (MS: N=16 vs. 10 age-matched controls), dystonia (Dys: N= 20 vs. 20 age-matched controls and systemic lupus erythematosus (SLE: N=20 vs. 20 age-matched controls). Plasma levels of proVGF derived products were quantified using competitive ELISA based on antibodies directed against the proVGF C-terminus. The PDN patients showed significant VGF reductions (p < 0.05) compared with controls, as did iRBD patients, who exhibited the same decreases (p < 0.05). In levodopa-treated patients, VGF changes were treatment-duration dependent: short-term therapy produced product-specific alterations whereas long-term treatment restored proVGF C-terminus levels toward control values. Correlation analyses revealed significant associations between proVGF product levels and clinical parameters related to disease duration and dopaminergic treatment. Interestingly, proVGF product levels were not changed in the other diseases. The overlap between iRBD and PDN supports the potential utility of specific VGF-derived products as blood-based biomarkers for identifying the premotor phase of PD for monitoring disease-related biological changes.

Downloads

Download data is not yet available.

Citations

How to Cite



1.
P011 | THE POTENTIAL OF VGF-DERIVED PRODUCTS AS PREDICTIVE BIOMARKERS OF PARKINSON’S DISEASE: A.L. Manai1, B. Noli1, A. Anjum1, M.M. Mascia2, M. Meloni2, K.I.R.M. Humaidan2, R.A. Filiberti3, M. Puligheddu2, C. Cocco1 | 1Department of Biomedical Sciences, NEF-Laboratory, University of Cagliari, Monserrato (CA), Italy; 2Neurology Unit, University Hospital of Cagliari, Italy; 3Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Eur J Histochem [Internet]. 2026 Nov. 20 [cited 2026 Nov. 20];70(s2). Available from: https://www.ejh.it/ejh/article/view/4831